ANTHRALIN CAS 1143-38-0
Introduction：Basic information about ANTHRALIN CAS 1143-38-0, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
ANTHRALIN Basic information
| Product Name: | ANTHRALIN |
| Synonyms: | DITHRANOL;9-anthrol;DITHRANOL, 97+%;1,8,9-ANTHRACENETRIOL, PGE. WITH 10 X 10 MG;1,8,9-Trihydroxyanthracene, 97+%;Anthraforte;Micanol;Psorider |
| CAS: | 1143-38-0 |
| MF: | C14H10O3 |
| MW: | 226.23 |
| EINECS: | 214-538-0 |
| Product Categories: | Skin drugs, treatment of psoriasis;API;ANTRADERM;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatic Phenols;1143-38-0 |
| Mol File: | 1143-38-0.mol |
ANTHRALIN Chemical Properties
| Melting point | 178-181 °C (lit.) |
| Boiling point | 464.1±45.0 °C(Predicted) |
| density | 1.419±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, soluble in methylene chloride, sparingly soluble in acetone, slightly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides. |
| form | Solid |
| pka | 7.16±0.20(Predicted) |
| color | Yellow to Orange to Dark Yellow |
| Water Solubility | Insoluble in water. Soluble in acetic acid, chloroform (20 mg/mL), acetone, benzene, solutions of alkali hydroxides, fixed oil. Slightly soluble in 95% ethanol, alcohol, ether, and glacial acetic acid. |
| Merck | 14,684 |
| BRN | 2054360 |
| Stability: | Stable. Combustible. Incompatible with strong oxidizing agents. |
| InChI | 1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16H,7H2 |
| InChIKey | NUZWLKWWNNJHPT-UHFFFAOYSA-N |
| SMILES | Oc1cccc2Cc3cccc(O)c3C(=O)c12 |
| CAS DataBase Reference | 1143-38-0(CAS DataBase Reference) |
| IARC | 3 (Vol. 13; Sup 7) 1987 |
| EPA Substance Registry System | Dithranol (1143-38-0) |
Safety Information
| Hazard Codes | Xi,T |
| Risk Statements | 36/37/38-45 |
| Safety Statements | 26-53-45 |
| WGK Germany | 3 |
| RTECS | CB8927000 |
| HS Code | 29144000 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 |
| Description | Anthralin is an anthrone inhibitor of keratinocyte proliferation and a modulator of differentiation. It increases apoptosis and inhibits proliferation of normal human keratinocytes (NHKs) when used at a concentration of 2.5 μM. It also decreases the mitochondrial membrane potential, increases cytochrome c release, and induces perinuclear mitochondrial clustering in NHKs when used at a concentration of 5 μM. Anthralin (0.25 μM) decreases the expression of β-defensin-2 and S100 calcium-binding protein A9 (S100A9) and increases the expression of IL-6 and IL-8 in IL-17A- and IL-22-stimulated NHKs. It also inhibits leukotriene B4 (LTB4; ) production, stimulated by the calcium ionophore A23187 , from human neutrophils (IC50 = 7 μM). Topical anthralin (0.1%) induces hair regrowth in a Dundee experimental bald rat (DEBR) model of alopecia areata. |
| Chemical Properties | Yellow Crystalline Solid |
| Uses | Antipsoriatic |
| Indications | Anthralin (Anthra-Derm) is a potent reducing agentwhose mechanism of action is unknown. It is approvedfor the treatment of psoriasis and also may be helpful inalopecia areata. The major toxicities are discolorationof skin, hair, and nails and irritant dermatitis. |
| Definition | ChEBI: An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9. |
| Brand name | Anthra-Derm (Dermik); DrithoCreme(Dermik); Drithoscalp (Dermik); Lasan (Stiefel). |
| General Description | Lemon yellow leaflets or plates or an orange powder. Melting point 176-181°C. No odor or taste. Insoluble in water. Moderately toxic by ingestion, inhalation and skin absorption. Used as a treatment for psoriasis. |
| Air & Water Reactions | Unstable in air when in alkaline solution. Insoluble in water. |
| Reactivity Profile | ANTHRALIN reacts as a weak acid. Soluble in aqueous bases. May react with strong oxidizing agents. May be sensitive to light and moisture . |
| Hazard | Very irritating. Do not use on scalp or near eyes. |
| Fire Hazard | Flash point data are not available for ANTHRALIN; however, ANTHRALIN is probably combustible. |
| Side effects | Anthralin's side effects include pruritus, erythema, scaling,folliculitis, and lymphadenopathy. Staining of skin and clothes can also be an issue. |
| References | [1] JULIA HOLSTEIN. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes[J]. Journal of dermatological science, 2017, 87 3: Pages 236-245. DOI: 10.1016/j.jdermsci.2017.06.007 [2] ALISON MCGILL. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria.[J]. FASEB Journal, 2005, 19 8: 1012-1014. DOI: 10.1096/fj.04-2664fje [3] SCHR?DER J M. Anthralin (1,8-Dihydroxyanthrone) Is a Potent Inhibitor of Leukotriene Production and LTB4-ω Oxidation by Human Neutrophils[J]. Journal of Investigative Dermatology, 1986, 87 5: Pages 624-629. DOI: 10.1111/1523-1747.ep12456188 [4] LIREN TANG. Old Wine in New Bottles: Reviving Old Therapies for Alopecia Areata Using Rodent Models[J]. Journal of Investigative Dermatology Symposium Proceedings, 2003, 8 2: Pages 212-216. DOI: 10.1046/j.1087-0024.2003.00812.x |
ANTHRALIN Preparation Products And Raw materials
| Preparation Products | Butantrone |
